Literature DB >> 6828303

Ocular toxicity of antineoplastic agents.

F T Fraunfelder, S M Meyer.   

Abstract

The increased use of chemotherapeutic agents has resulted in longer patient survival; consequently, the ophthalmologist is seeing more patients with adverse ocular side effects secondary to these antineoplastic agents. Many of these drugs cause aggravating ocular irritation (fluorouracil, methotrexate), canalicular fibrosis with epiphora (fluorouracil), retinopathy (mitotane, tamoxifen), corneal opacities (tamoxifen), cataracts (busulfan, methotrexate), and optic or ocular motor abnormalities (carmustine, vinblastine, vincristine). Based on the data in the National Registry of Drug-Induced Ocular Side Effects and the literature, adverse ocular reactions of the more commonly used chemotherapeutic agents are reviewed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6828303     DOI: 10.1016/s0161-6420(83)34600-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

Review 1.  Immunosuppression in uveitis therapy.

Authors:  R N Van Gelder; H J Kaplan
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Bilateral total corneal epithelial erosion as a side effect of cytotoxic therapy.

Authors:  A Hirsh; A Alhalel; A Weiss; H Brener; I Avni
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

3.  Dry eye after haematopoietic stem cell transplantation.

Authors:  Y Ogawa; S Okamoto; M Wakui; R Watanabe; M Yamada; M Yoshino; M Ono; H Y Yang; Y Mashima; Y Oguchi; Y Ikeda; K Tsubota
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

Review 4.  Late effects of total body irradiation.

Authors:  A D Leiper
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

Review 5.  Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation.

Authors:  Jean E Sanders
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Cyclophosphamide for ocular inflammatory diseases.

Authors:  Siddharth S Pujari; John H Kempen; Craig W Newcomb; Sapna Gangaputra; Ebenezer Daniel; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; C Stephen Foster
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

7.  Patterns of reinnervation and motor unit recruitment in human hand muscles after complete ulnar and median nerve section and resuture.

Authors:  C K Thomas; R B Stein; T Gordon; R G Lee; M G Elleker
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-03       Impact factor: 10.154

8.  Effects of selected repeated intravitreal chemotherapeutic agents.

Authors:  J Vernot; G A Peyman; R Gailitis; R Fiscella; M Woodhouse; D Weinberg
Journal:  Int Ophthalmol       Date:  1985-11       Impact factor: 2.031

9.  Orbital rhabdomyosarcoma: improved survival with combined pulsed chemotherapy and irradiation.

Authors:  S Y Ghafoor; J Dudgeon
Journal:  Br J Ophthalmol       Date:  1985-08       Impact factor: 4.638

10.  Cataract development and outcome of surgery in bone marrow transplanted children.

Authors:  B M Calissendorff; P Bolme
Journal:  Br J Ophthalmol       Date:  1993-01       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.